The present invention relates to the treatment of autonomic disorders with a clostridial neurotoxin comprising a HCC domain from a BoNT/B, BoNT/D, BoNT/D-C, BoNT/F or BoNT/G, wherein the dose of the clostridial neurotoxin to be administered to the patient is equivalent to or lower than the dose of BoNT/A that would be used to treat the same autonomic disorder.本發明係關於以包含來自BoNT/B、BoNT/D、BoNT/D-C、BoNT/F或BoNT/G之HCC域的梭菌神經毒素治療自主神經系統障礙，其中該欲投予至病患之梭菌神經毒素的劑量係等於或低於將用於治療相同自主神經系統障礙的BoNT/A劑量。
